December 31, 2014
2014
- ReadPradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. Comparative pharmaco-economic assessment of apixaban versus standard of care for the prevention of stroke in Italian atrial fibrillation patients. Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 15-25
- ReadPradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients. Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 5-14
- ReadPradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. Cost effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients. Farmeconomia. Health economics and therapeutic pathways 2014; 15(4): 101-112
- ReadMancini N, Sambri V, Corti C, Ghidoli N, Tolomelli G, Paolucci M, Clerici D, Carletti S, Greco R, Tassara M, Pizzorno B, Zaniolo O, Povero M, Pradelli L, Burioni R, Stanzani M, Landini MP, Ciceri F, Clementi M. Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis: an observational propensity score-matched study. Expert Rev Mol Diagn 2014; 14(5): 623-32
- ReadPradelli L, Eandi M, Povero M, Mayer K, Muscaritoli M, Heller AR, Fries-Schaffner E. Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model. Clin Nutr 2014; 33(5): 785-92
- ReadPovero M, Pradelli L, Turco P, Dal Negro RW. Real-life cost and cost-effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48-month survey. Farmeconomia. Health economics and therapeutic pathways 2014; 15(2): 39-44
No Comments
Sorry, the comment form is closed at this time.